Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Diffuse Glioma

No OncoTree code · 2 articles

Clinical · Molecular biology

Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations

Seifert AM, Richter S, Sagerer A, et al.

Journal of neuro-oncology

This study compared clinical characteristics and survival between molecularly defined IDH-wild-type glioblastoma (MolGBM) and histologically defined IDH-wild-type glioblastoma (HistGBM). It also characterized lower-grade IDH-wild-type astrocytic tumors lacking glioblastoma-defining genomic alterations. MolGBM exhibited a more favorable adjusted overall survival (HR 0.40) compared to HistGBM, particularly in patients aged 60 years or older. These findings highlight the clinical and biological heterogeneity among molecularly defined IDH-wild-type diffuse gliomas and the critical role of comprehensive molecular characterization. Lower-grade IDH-wild-type astrocytic tumors without glioblastoma-defining alterations warrant further in-depth molecular investigation.

Molecular biology

Invasion/metastasis-related differentially methylated genes predict prognosis in diffuse gliomas

Zhang S, Sun Z, Jiang S, et al.

Journal of neuro-oncology

This study identified invasion/metastasis-related differentially methylated genes (DMGs) with prognostic relevance in diffuse gliomas. A risk model was constructed using two marker genes, ERRFI1 and MYO1G, demonstrating robust predictive performance in both training and independent validation cohorts. Patients classified as high-risk exhibited worse overall survival and altered immune infiltration. In vitro functional validation showed that knockdown of ERRFI1 or MYO1G inhibited glioma cell proliferation, invasion, and migration, with potential involvement of the EGFR/MAPK/ERK pathway.